Reported Q1 2026 revenue of $2.65 million, a 5.6% decrease from $2.81 million in Q1 2025. Net loss attributable to stockholders was $0.93 million for the quarter, compared to $0.71 million in the prior year period. Operating expenses increased to $2.02 million, driven by higher professional and consulting fees. Successfully raised $7.375 million in April 2026 and an additional $1.21 million in May 2026 through private placements of convertible notes. Completed the acquisition of Celularity's regenerative biomaterials portfolio for $13.3 million in total consideration.